Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
Key Highlights
- ➤Optimi establishes wholly owned Optimi Australia for local distribution and business development
- ➤Australia operations will sell 5mg psilocybin and 40mg and 60mg MDMA capsules
- ➤Adrian Jones appointed Director of Australian Operations after 15 years at Bristol Myers Squibb
- ➤Optimi products are prescribed in Australia under the Authorised Prescriber Scheme
- ➤Optimi plans Phase 2 psilocybin and proposed Phase 3 MDMA clinical trials
Expert Statements
Dane Stevens, Chief Executive Officer of Optimi Health Corp.
“Australia is our first commercial market and we believe demand from authorized prescribers there continues to grow,”
Dane Stevens, Chief Executive Officer of Optimi Health Corp.
“Optimi Australia puts our team on the ground, and in Adrian we have a leader with extensive experience launching new therapies in this market.”
Adrian Jones, Director of Australian Operations at Optimi Australia Pty Ltd
“My immediate focus is to understand the needs of the clinician and to help them deliver therapy as efficiently and effectively as possible,”
VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical developer and manufacturer of regulated psychedelic drug products, today announced the establishment of Optimi Australia Pty Ltd ("Optimi Australia"), a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations.
Optimi Australia will handle the Company's sales, distribution, and prescriber relationships across the country. It will sell Optimi's finished drug products, 5mg naturally derived psilocybin capsules and 40mg and 60mg MDMA capsules, to clinics and pharmacies under Australia's Authorised Prescriber Scheme. All products are manufactured at the Company's Health Canada-licensed GMP facility in Princeton, British Columbia.
Get started
Create a free account to read the full story.